Last reviewed · How we verify

APG777 — Competitive Intelligence Brief

APG777 (APG777) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: multikinase inhibitor. Area: Oncology.

phase 2 multikinase inhibitor FGFR1, FGFR2, FGFR3 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

APG777 (APG777) — Apogee Therapeutics, Inc.. APG777 is a multikinase inhibitor targeting FGFR1, FGFR2, and FGFR3.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
APG777 TARGET APG777 Apogee Therapeutics, Inc. phase 2 multikinase inhibitor FGFR1, FGFR2, FGFR3
Trifluridine/Tipiracil + Regorafenib Trifluridine/Tipiracil + Regorafenib Second Affiliated Hospital, School of Medicine, Zhejiang University phase 3 Nucleoside analog + multikinase inhibitor combination Thymidylate synthase (trifluridine/tipiracil); VEGFR, FGFR, KIT, RET, BRAF (regorafenib)
Regorafenib (BAY73-4506) Regorafenib (BAY73-4506) Bayer phase 3 Multikinase inhibitor VEGFR1-3, FGFR, TIE2, KIT, RET, RAF-1, BRAF

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (multikinase inhibitor class)

  1. Apogee Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APG777 — Competitive Intelligence Brief. https://druglandscape.com/ci/apg777. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: